| 查看: 108 | 回复: 0 | |||
| 当前主题已经存档。 | |||
[交流]
Sanofi Obesity Drug Gets Final Okay From UK's NICE
|
|||
|
LONDON (Reuters) Jun 25 - Sanofi-Aventis won a final green light for its obesity drug Acomplia (rimonabant) from Britain's cost-effectiveness watchdog NICE on Wednesday, clearing the way for doctors to prescribe it on the state health service. The move was expected following a positive appraisal from the National Institute for Health and Clinical Excellence (NICE) in March. It marks a small positive for the French drugmaker's once much-hyped medicine, which has failed to live up to early expectations. NICE's final guidance recommends using Acomplia as an addition to diet and exercise for obese or overweight adults who don't respond to or are intolerant of two other weight-loss drugs, orlistat and sibutramine. But NICE cautioned that treatment should not continue beyond 6 months unless patients lost at least 5 percent of their initial body weight and there should, in any event, be a formal clinical assessment after 2 years. The UK decision contrasts with Germany where Acomplia is not reimbursed by health insurers because it is deemed simply to improve lifestyle. Acomplia was once touted as a multibillion-dollar seller, but hopes for the product dimmed last year when a U.S. expert panel recommended against its approval in the world's biggest market, after it was linked to rare cases of suicidal thoughts. Sanofi said in October it expected only limited sales of the drug in the next few years, until new clinical trial results testing it in diabetes are ready for submission to regulators in 2009. Worldwide sales of the drug were a meagre 79 million euros ($122.9 million) last year. Roche makes the older weight-loss drug orlistat under the brand name Xenical, while sibutramine is marketed by Abbott Laboratories under the brand names Meridia or Reductil. |
回复此楼» 猜你喜欢
医学类教育学类 简单易中的中文核心
已经有1人回复
-
对作者单位没有歧视的核心期刊
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有192人回复
-
导师咨询
已经有5人回复
-
丙酮酸激酶的抑制剂和激动剂
已经有1人回复
-
脓毒症（盲肠结扎）
已经有22人回复
-
博导推荐
已经有2人回复
-
哪里做甘氨酸受体与配体结合率的试验
已经有0人回复
-
关于SCI杂志发表挂名
已经有32人回复
